Stereochemistry | ACHIRAL |
Molecular Formula | C16H7N2O5.Na |
Molecular Weight | 330.2269 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].OC1=CC(=NC2=C1C3=NC4=CC=CC=C4OC3=CC2=O)C([O-])=O
InChI
InChIKey=HDQXPMXHXZNPKE-UHFFFAOYSA-M
InChI=1S/C16H8N2O5.Na/c19-9-5-8(16(21)22)18-14-10(20)6-12-15(13(9)14)17-7-3-1-2-4-11(7)23-12;/h1-6H,(H,18,19)(H,21,22);/q;+1/p-1
Pirenoxine is an anti-cataract agent which is used in many asian countries under the name Catalin. Although its efficacy is not proved scientifically, the drug may play an important role in cataract prevention. It is supposed that the anti-cataract effect of pirenoxine results from inhibition of sulfhydryl combination of quinoid substances with lens proteins and the inhibition leads to the maintenance of lens transparency.
Approval Year
PubMed
Patents
Sample Use Guides
Dissolve the granules (0.75 mg) in 15 ml of the vehicle just before use and instill 1-2 drops of the
solution, 3-5 times a day
Route of Administration:
Other
Pirenoxine (1,000 uM) decreased UVC-induced turbidity formation compared to controls after 4 h of UVC exposure. The absolute gamma-crystallin turbidity induced by 4 h of UVC exposure was ameliorated in the presence of catalin equivalent to 1-100 uM of the drug in a concentration-dependent manner. Pirenoxine at 0.03, 0.1, and 0.3 uM significantly delayed 10 mM selenite- and calcium-induced turbidity formation compared to controls on days 0-4.